NAD⁺ IV Infusion Protocol

Overview

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every living cell — a molecule so fundamental to cellular metabolism that its depletion is considered one of the primary biochemical hallmarks of aging. It functions as the principal electron carrier in the mitochondrial energy production chain, but its importance extends far beyond energy metabolism: it is a required substrate for sirtuin deacylase enzymes (the "longevity proteins"), for PARP (poly ADP-ribose polymerase) DNA repair enzymes, and for multiple other cellular maintenance systems.

NAD+ levels decline approximately 50% between early adulthood and the sixth decade of life. This decline is not incidental — research from Sinclair, Guarente, and others over the past 15 years has established that NAD+ depletion drives the downstream functional decline in mitochondrial efficiency, DNA repair capacity, and cellular stress resistance that characterises biological aging. Restoring NAD+ levels is accordingly one of the most scientifically grounded targets in longevity medicine.

The Biochemistry of NAD+ in Aging

Mitochondrial Energy Production

NAD+ accepts electrons from glucose and fatty acid catabolism, becoming NADH. NADH is oxidised back to NAD+ in the mitochondrial electron transport chain, generating ATP. When NAD+ pools are depleted, this cycle slows — producing the fatigue, cognitive fog, and reduced exercise tolerance characteristic of biological aging and of various NAD+-depleting disease states.

Sirtuin Activation (SIRT1-7)

Sirtuins are a family of seven NAD+-dependent deacylase enzymes that regulate gene expression, DNA repair, mitochondrial biogenesis, inflammation, and metabolic homeostasis. They are non-functional without NAD+ as a cofactor. SIRT1 and SIRT3 — the most studied — deacetylate histone proteins and transcription factors to silence inflammatory genes and activate mitochondrial biogenesis pathways. SIRT6 is involved in DNA double-strand break repair. NAD+ depletion silences all sirtuin activity; NAD+ repletion restores it.

PARP-Mediated DNA Repair

PARP enzymes are DNA damage sensors that detect single-strand breaks and recruit repair machinery. They consume NAD+ stoichiometrically in their repair activity — and in aging, cumulative DNA damage and chronic PARP activation are a significant driver of NAD+ depletion, creating a vicious cycle: DNA damage → PARP activation → NAD+ depletion → impaired sirtuin activity → further DNA damage. IV NAD+ repletion breaks this cycle by restoring the substrate pool.

IV vs Oral NAD+ Precursors

Oral NAD+ precursors — nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) — are widely available as supplements and do elevate blood NAD+ levels. The argument for IV administration is bioavailability and speed of cellular repletion: IV NAD+ bypasses gastrointestinal absorption variability, first-pass hepatic metabolism, and the rate-limiting steps of intracellular conversion from precursors. In patients with significantly depleted NAD+ levels or those seeking rapid and confirmed repletion, IV administration provides a level of certainty and dose control that oral supplementation cannot match. For ongoing maintenance, oral NR or NMN supplementation is typically combined with periodic IV repletion.

Clinical Protocol

An initial loading series typically consists of 4–10 infusions over 1–3 weeks — the frequency depends on the indication and the practitioner's protocol. Each infusion delivers 250–1000 mg of NAD+ in normal saline over 2–4 hours. The infusion rate is carefully managed: too rapid an infusion produces characteristic side effects (see below) that resolve immediately upon rate reduction but are uncomfortable. Starting at lower doses (250 mg) and titrating up over subsequent sessions is standard practice. Maintenance infusions are scheduled monthly to quarterly thereafter.

What Patients Report

The subjective experience of NAD+ repletion varies between patients. Commonly reported effects in the days to weeks following an initial loading series include improved energy and reduced fatigue, improved cognitive clarity ("brain fog" reduction), improved sleep quality, and improved exercise performance and recovery. These subjective reports are consistent with the known biology of NAD+-dependent mitochondrial and neurological function, though large-scale placebo-controlled trials in healthy aging populations remain limited.

Cost in the United States

NAD+ infusions range from $600–$2,000 per session depending on dose, infusion duration, and practice setting. A full initial loading series (6–10 sessions) typically ranges from $3,000–$10,000. Maintenance single sessions are $600–$1,200 in most markets. The cost reflects both the NAD+ raw material cost and the supervised clinical time required for a 2–4 hour monitored infusion.

Risks and Contraindications

• Infusion-rate side effects: Flushing, chest tightness, nausea, gastrointestinal cramping, and headache during infusion are common at higher rates — resolved by slowing the infusion. These are not allergic reactions.
• Theoretical oncological concern: NAD+ supports cellular metabolism in both healthy and malignant cells. In patients with active or recent malignancy, the systemic metabolic stimulation from NAD+ repletion is a theoretical concern that should be discussed with the treating oncologist. NAD+ therapy is generally not offered to patients with active cancer.
• Pre-existing NAD+ pathway conditions: Patients with known polymorphisms in NAMPT or SIRT pathways may respond differently.

Contraindications: Active malignancy, pregnancy, haemophilia or severe coagulopathy, and known NAD+ hypersensitivity (rare).